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To the Editor: 
Exercise-induced bronchoconstriction (EIB) refers to a condition characterised by expiratory airflow 
limitation during physical activity and is one of the most common causes of exertional breathing 
difficulty in young athletic individuals 1. Due to the limited value of a symptom-based approach to 
diagnosis 2 it is now widely recognised that EIB should be objectively confirmed via indirect 
bronchoprovocation testing before initiating treatment, with eucapnic voluntary hyperpnoea (EVH) 
often endorsed for this purpose 3. Although the feasibility of EVH testing is well established, the 
practicalities and associated cost of assessment is substantial and therefore not widely available as part 
of routine diagnostic work-up across primary and secondary care. The development of simple yet robust 
clinical tools to aid the assessment of airway health in athletic individuals is therefore required.  
The Allergy Questionnaire for Athletes (AQUA) was originally developed and validated as a reliable 
means to quantify the severity of allergic disease in athletes (specificity: 97.1% and sensitivity: 58.3%) 
4. Over the past decade, the relevant respiratory symptom components of AQUA have also been 
employed in studies evaluating perceived dyspnoea and respiratory tract infection 2,5 - leading to the 
suggestion that AQUA may offer value as a pre-screening tool for the assessment of airway health in 
susceptible or ‘high-risk’ athletic populations (e.g. elite level swimmers) 6. Although utilising AQUA in 
this context is logical on the basis that airway hyper-responsiveness (AHR) and asthma are strongly 
associated with atopic disposition 7, the agreement with objective test outcome following indirect 
bronchoprovocation testing has yet to be determined. We therefore undertook this study to evaluate the 
predictive value of AQUA to confirm or refute evidence of EIB in a large cohort of screened athletes.  
The study was conducted as a multi-site cross-sectional trial. Following approval from local research 
ethics committees (Ethics ID: 57144), one-hundred and eighty recreational athletes (male: n = 120) 
provided written informed consent (Table 1.). At study entry, exertional respiratory symptoms (i.e. 
cough, wheeze, chest tightness and dyspnoea) were evaluated via interview with all athletes completing 
AQUA followed by an EVH challenge. The EVH protocol consisted of breathing a dry compressed gas 
mixture (21% O2, 5% CO2, balance N2) at a target ventilation equivalent to 85% maximum voluntary 
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ventilation (MVV) for a period of 6-min. To ensure test validity (i.e. avoid false-negative test outcome) 
all athletes were required to achieve ≥60% predicted MVV. Spirometry was performed in triplicate at 
baseline and in duplicate at 3, 5, 7, 10, and 15-min post EVH. A positive AQUA questionnaire was 
defined by a score ≥5 4. Sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) were calculated and evaluated against objective evidence of EIB in accordance with current 
committee guidance (-10% ΔFEV1 at two consecutive time-points) 3 and a recently suggested revised 
EVH diagnostic cut-off (-15% ΔFEV1 at one time-point) 8. Diagnostic accuracy of AQUA was 
calculated using receiver operating characteristics area under the curve (ROC-AUC). 
Almost all athletes (99%) had normal baseline lung function (FEV1 % predicted ≥80%). Despite this, 
over half of the cohort (55%) reported at least one respiratory symptom during exercise. Over one-third 
(37%) of the cohort had a prior asthma diagnosis, however, of these, only thirty-one (46%) (-10% 
ΔFEV1) and nineteen (28%) (-15% ΔFEV1) presented with objective evidence of EIB. One hundred and 
twenty-nine athletes (72%) provided a positive AQUA score indicating a high likelihood of allergic 
disease. The prevalence of EIB for the entire cohort was 21% (-10% ΔFEV1) and 14% (-15% ΔFEV1). 
ROC-AUC for AQUA was 66% (-10% ΔFEV1) and 69% (-15% ΔFEV1), respectively. Irrespective of 
test outcome or asthma history, the majority of athletes (96%) experienced bronchoconstriction post 
EVH (average fall in FEV1 -8.9 ± 10.1%). The predictive value of AQUA for the detection of EIB is 
presented in Table 2.  
The present study highlights that a positive AQUA score (≥5) provides poor diagnostic specificity (32%) 
(i.e. ability to rule-in EIB). This finding supports the concept that AQUA and/or self-report respiratory 
symptoms should not be used to confirm a diagnosis in the absence of indirect bronchoprovocation 
testing 2. Importantly, however, for the first time, our data indicate that a negative AQUA score (<5) 
offers excellent diagnostic sensitivity (i.e. ability to rule-out EIB). This was apparent when applying 
either current (92%) 3 or revised diagnostic thresholds (98%) 8. Furthermore, in those with evidence of 
moderate to severe bronchoconstriction (i.e. ≥20% fall in FEV1), a negative AQUA score ruled-out EIB 
in all cases. Of note, in the very few athletes with a negative AQUA score and evidence of EIB (2%), 
the majority provided a positive response to the relevant respiratory symptom components of the 
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questionnaire; i.e. Q10: “Did you ever feel tightness of your chest and/or wheeze” and Q13: “Have you 
ever had shortness of breath, cough and/or itching of the throat following exercise”. 
The clinical relevance of our findings are perhaps most applicable in a primary care setting where it is 
commonplace to encounter athletic individuals reporting breathing difficulty during exercise. Indeed, 
when faced with this clinical presentation, athletes are most frequently prescribed a course of inhaler 
therapy (in the absence of objective assessment) for presumed EIB. This is despite increasing 
recognition that a broad differential diagnosis exists for breathing difficulty in athletes; i.e. not all 
wheeze is asthma 9. Accordingly, utilising AQUA as an initial form of assessment, particularly in 
susceptible athletes who train and compete in irritant-laden environments (e.g. high aeroallergen) offers 
a reliable and time-efficient approach to aid clinical decision-making; i.e. inform referral for specialist 
objective testing and/or consider differential diagnosis. For example, exercise-induced laryngeal 
obstruction (EILO); a condition characterised by closure of the upper airway (i.e. laryngeal structures) 
during exercise is highly prevalent in young athletes (~5-10%) yet frequently overlooked 9. Similarly, 
incorporating AQUA in the context of widespread screening (e.g. sports teams or squads) offers a 
practical and cost-effective approach to ensure airway health is optimised and maintained.  
In summary, AQUA is a simple tool that provides value in the assessment of EIB in athletes and should 
be utilised as a ‘first-step’ to rule-out the condition during diagnostic work-up. The development and 
validation of an athlete specific questionnaire and risk prediction algorithms to confirm (i.e. rule-in) EIB 
remains an important avenue for future research.  
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Table 1. Study population clinical characteristics.  
Variables  Distribution Mean (± SD) Median (IQR) 
Age (years)  Non-normal 33  ± 10 31  (16) 
Height (cm) Normal 175  ± 9 175  (13) 
Weight (kg) Non-normal 73  ± 13 73  (15) 
BMI (kgm-2) Non-normal 24  ± 3 23  (4) 
Training (hrswk-1) Non-normal 7  ± 3 6  (3) 
FEV1 (L) Normal 3.92  ± 0.73 3.84  (1.12) 
FEV1 % predicted Non-normal 102  ± 12 100  (16) 
FVC (L) Normal 4.84  ± 0.89 4.85  (1.40) 
FVC % predicted Non-normal 106  ± 12 105  (15) 
FEV1/FVC (%) Normal 82  ± 7 82  (10) 
AQUA score Non-normal 9  ± 7 9  (12) 
Eucapnic voluntary hyperpnoea       
Average fall in FEV1 (%) Non-normal -8.9  ± 10.1 -5.5  (6.3) 
Target ventilation (L) Normal 118  ± 22 115  (34) 
Achieved ventilation (L) Normal 97  ± 24 99  (32) 
Predicted ventilation (%) Non-normal 78  ± 23 83  (21) 
 Ratio (percentage) 
Sporting discipline   
Endurance 151/180 (84%) 
Intermittent 21/180 (12%) 
Sprint/power 8/180 (4%) 
Physician diagnosed asthma 67/180 (37%) 
EIB positive (-10% ΔFEV1) 31/67 (46%) 
EIB negative (-10% ΔFEV1) 36/67 (54%) 
EIB positive (-15% ΔFEV1) 19/67 (28%) 
EIB negative (-15% ΔFEV1) 48/67 (72%) 
Inhaler medication  
Reliever therapy  27/67 (40%) 
Reliever + maintenance therapy 40/67 (60%) 
 
 
  
6 
 
Table 2. AQUA sensitivity, specificity, PPV and NPV value for the detection of EIB.  
Population: n = 180 
 Prevalence (-10% ΔFEV1): 21% 
Prevalence (-15% ΔFEV1): 14% 
 EVH  
  -10% ΔFEV1  -15% ΔFEV1 
 + -  + - 
AQUA score  
+ 33 96 + 24 105 
- 4 47 - 1 50 
  AQUA score  
 -10% ΔFEV1  -15% ΔFEV1 
Sensitivity (%) 89  96 
Specificity (%) 32  32 
PPV (%) 26  19 
NPV (%) 92  98 
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